These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26238110)

  • 1. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
    Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
    Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing medicine price transparency through price information mechanisms.
    Hinsch M; Kaddar M; Schmitt S
    Global Health; 2014 May; 10():34. PubMed ID: 24885767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retail prices of essential drugs in Brazil: an international comparison.
    Nóbrega Ode T; Marques AR; de Araújo AC; Karnikowski MG; Naves Jde O; Silver LD
    Rev Panam Salud Publica; 2007 Aug; 22(2):118-23. PubMed ID: 17976278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of State-Level Drug Pricing Transparency Laws in the United States.
    Ryan MS; Sood N
    JAMA Netw Open; 2019 Sep; 2(9):e1912104. PubMed ID: 31553467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral drug expenditure, pricing and judicial demand: an analysis of federal procurement data in Brazil from 2004-2011.
    Luo J; Oliveira MA; Ramos MB; Maia A; Osorio-de-Castro CG
    BMC Public Health; 2014 Apr; 14():367. PubMed ID: 24735589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.
    Dave CV; Pawar A; Fox ER; Brill G; Kesselheim AS
    Value Health; 2018 Nov; 21(11):1286-1290. PubMed ID: 30442275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing of HPV tests in Italian tender-based settings.
    Inturrisi F; Berkhof J
    J Med Econ; 2022; 25(1):762-768. PubMed ID: 35616231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment.
    Mahlich J; Kamae I; Sruamsiri R
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):339-348. PubMed ID: 29039214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assistive technology pricing in Australia: is it efficient and equitable?
    Summers MP; Verikios G
    Aust Health Rev; 2018 Feb; 42(1):100-110. PubMed ID: 28160784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of branded prescription medicine prices in OECD countries.
    Kanavos PG; Vandoros S
    Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.